Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
TENOFOVIR DISOPROXIL FUMARATE; EMTRICITABINE
PHARMASCIENCE INC
J05AR03
TENOFOVIR DISOPROXIL AND EMTRICITABINE
300MG; 200MG
TABLET
TENOFOVIR DISOPROXIL FUMARATE 300MG; EMTRICITABINE 200MG
ORAL
30
Prescription
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS
Active ingredient group (AIG) number: 0251568001; AHFS:
APPROVED
2017-07-26
PRODUCT MONOGRAPH Pr PMS-EMTRICITABINE-TENOFOVIR Emtricitabine and Tenofovir Tablets 200 mg / 300 mg (Emtricitabine / Tenofovir Disoproxil Fumarate) House Standard Antiretroviral Agent PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Canada H4P 2T4 www.pharmascience.com Date of Preparation: November 26, 2020 Submission Control No: 245065 _ _ _pms-EMTRICITABINE-TENOFOVIR Product Monograph _ _Page 2 of 65_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................5 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................14 DRUG INTERACTIONS ..................................................................................................21 DOSAGE AND ADMINISTRATION ..............................................................................32 OVERDOSAGE ................................................................................................................35 ACTION AND CLINICAL PHARMACOLOGY ............................................................36 STORAGE AND STABILITY ..........................................................................................39 SPECIAL HANDLING INSTRUCTIONS .......................................................................39 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................39 PART II: SCIENTIFIC INFORMATION ...............................................................................40 PHARMACEUTICAL INFORMATION ........................................................ Կարդացեք ամբողջական փաստաթուղթը